Danish drugmaker Novo Nordisk is facing two shareholder class actions in federal court accusing it of inflating its earning prospects and engaging in collusive pricing of its insulin drugs for diabetics.
January 19, 2017 at 04:46 PM
1 minute read
Danish drugmaker Novo Nordisk is facing two shareholder class actions in federal court accusing it of inflating its earning prospects and engaging in collusive pricing of its insulin drugs for diabetics.
The latest suit, Zuk v. Novo Nordisk, was filed Wednesday. It comes on the heels of a similar case, Lehigh County Employees’ Retirement System v. Novo Nordisk, which was filed Jan. 11.
Presented by BigVoodoo
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Consulting Magazine recognizes leaders in technology across three categories Leadership, Client Service and Innovation.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
